Vertice Launches With Up To $300m For Specialty Pharma Deals
This article was originally published in Scrip
While the big fish in the biopharma ocean are swallowing up all of the small fish, Vertice Pharma LLC is swimming against the tide with up to $300m from Warburg Pincus to support the startup's specialty pharmaceuticals strategy, starting with the acquisition of VistaPharm.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.